Beyond TME Origins
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorImperial College London
About this trial
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
Eligibility criteria
Qualifiers
Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice
Has a confirmed diagnosis of recurrent pelvic colorectal cancer
Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum
Are able to undergo high resolution MRI for staging prior to treatment decisions
Disqualifiers
Have irresectable extra-pelvic metastatic disease
Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable
Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable
Trial design
Treatments tested in this trial
- New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
Treatment groups
383 Participants
are divided into 1 treatment groupSponsors and collaborators
Imperial College London
Lead sponsor
Pelican Cancer Foundation
Collaborator
Source ClinicalTrials.gov